Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs

Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant progress on clinical and lifecycle milestones.

The company generated $125 million in annual net sales for Revuforj and $152 million for Niktimvo in the first 11 months. Consequently, the products are showing quarter-over-quarter sales growth. Revuforj’s revenue growth is driven by continued penetration in its labeled indication for KMT2A-rearranged acute myeloid leukemia.

In addition, the company is staring at a tremendous opportunity with Niktimvo in chronic GVHD, targeting 6,500 patients that could expand to about 17,000. Consequently, the company could generate up to $1 billion in third-line plus sales. Syndax has a strategic collaboration with Incyte to co-promote the product.

Syndax Pharmaceuticals (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative, first-in-class, targeted therapies for cancer, particularly acute leukemia and chronic graft-versus-host disease (cGVHD). They are known for FDA-approved drugs Revuforj (revumenib) and Niktimvo (axatilimab-csfr).

While we acknowledge the potential of SNDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.